BTI-322 for induction therapy after renal transplantation: a randomized study

Transplant Proc. 1997 Feb-Mar;29(1-2):317-9. doi: 10.1016/s0041-1345(96)00282-5.

Authors

J P Squifflet¹, T Besse, J Malaise, M Mourad, C Delcorde, J A Hope, Y Pirson

Affiliation

¹ Department of Renal and Pancreatic Transplantation, Cliniques UCL Saint-Luc, Brussels, Belgium.

PMID: 9123018
DOI: 10.1016/s0041-1345(96)00282-5

No abstract available

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Azathioprine / therapeutic use
Cyclosporine / therapeutic use
Graft Rejection / epidemiology
Graft Rejection / prevention & control*
Graft Rejection / therapy*
Graft Survival*
Humans
Immunosuppression Therapy*
Immunosuppressive Agents / therapeutic use*
Kidney Transplantation / immunology*
Kidney Transplantation / mortality
Prednisolone / therapeutic use
Survival Rate
Transplantation, Homologous

Substances

Antibodies, Monoclonal
Immunosuppressive Agents
LO-CD2a
Cyclosporine
Prednisolone
Azathioprine